There have been several reports of akathisia associated with the use of selective serotonin reuptake inhibitors (SSRIs), usually rapid in onset and occurring within days of drug initiation (l). This report describes the case of a patient who developed delayed-onset or tardive akathisia with paroxetine treatment.
Case Report
Mr A was a 38-year-old male with obsessive-eompulsive disorder (OCD), with compulsions to view morgues and operating rooms. In addition, he suffered from multiple paraphilias, including pedophilia, exhibitionism, and voyeurism. He was born prematurely to a mother who had abused drugs and alcohol throughout the pregnancy, and he had a cleft lip and palate repaired after birth. He also had significant facial dysmorphism. Despite this background, he had a normal to aboveaverage intellect and good insight into his psychiatric problems. He was compliant with his treatment, with few emergency visits and no history of drug-seeking behaviour.
He had been treated with paroxetine 70 mg 4 times per day for 2 years for his OCD. In addition, he received leuprolide (Lupron) 7.5 mg intramuscular (1M) every 4 weeks for 7 years for his paraphilias, and alendronate (Fosamax) 5 mg 4 times per day for 3 years for osteoporosis. Previously, a trial of clomipramine had also been used for his OCD. In addition, a diagnosis ofTourette syndrome had been considered in his past because of the presence of motor tics, which resulted in the trial of pimozide 3 years ago. However, this medication was stopped shortly thereafter because the patient developed an acute akathisia.
At this time, Mr A presented with a subjective inner restlessness, which he described as being identical to his reaction to pimozide 3 years previously. Objectively, he was noted to have restless leg movements. There had been no change to his medication regimen for 2 years. He was started on lorazepam 1 mg 3 times daily in the afternoon, and all complaints ofrestlessness disappeared after 4 days. No further treatment or medication change was required.
Discussion
Tardive akathisia is defined as an akathisia of delayed onset, in the absence of a change of drug dose or type within 3 months (2) . The incidence of acute akathisia with neuroleptics is in the range of20% to 30% (3), compared with 9.8% to 25% for SSRIs (l). The incidence of tardive akathisia with Can) Psychiatry, Vol 45, March 2000 neuroleptics has been reported to be between 18% and 41% (2) . Tardive akathisia has not been reported previously in relation to drugs other than antipsychotics (2) . While the differential diagnosis for this case could include anxiety related to the patient's OCD, or his combination ofhis medications, the subjective similarity to the previous akathisia and its quick resolution with lorazepam led to a diagnosis of tardive akathisia. Ofhis 3 medications, paroxetine was the only psychoactive substance, and thus was the most likely cause of this reaction. Given this patient's complex medical history, there may have been a genetic predisposition to the development of akathisia present in this particular case. It has been suggested that SSRIs may inhibit dopaminergic neuronal activity in the ventral tegmental area to produce akathisia (4). While previous reports have indicated that the clinician must be aware of the possibility of akathisia when initiating an SSRI, this case illustrates that this side effect may occurwithout a recent change in the medication.
Ernie Boffa, MD Jodi Lofchy, MD,FRCPC Toronto, Ontario
Obsessive-Compulsive Disorder With Onset in Old Age
Dear Editor:
The 6-month and the lifetime prevalence of obsessive-compulsive disorder (OCD) is 0.7%-2.1% and 1.9%-3.1% respectively (1) . While the prevalence rate in the Epidemiologic Catchment Area (ECA) study in the 65 years and over age group was 1.2% (2), it is uncommon for OeD to begin for the first time in life in old age (3), although obsessive-eompulsive symptoms have been known to occur forthe first time in life in this age group, secondary to other illnesses.
Case Report
Mrs G is a 75-year-old widow who presented with compulsions regarding washing, bathing, and checking, and obsessive thoughts about past events, of 5 months duration. All hematological and biochemical parameters (for renal and liver functions, lipid profile, and glucose levels) were normal.
An electrocardiograph (ECG) showed nonspecific T-wave changes. A visual and computerized electroencephalograph (EEG) revealed no abnormality. Her CT Scan showed diffuse cerebral and cerebellar atrophy. Cerebrospinal fluid studies for chronic meningeal infection were negative. The patient was treated with 50 mg daily of Sertraline, which was increased to a maximum of 100 mg daily. Her score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) from 17 to 11 at the time of discharge, and she was noted to have ! moderately improved.
This case documents the unusual occurrence of OCD for the first time in old age with no comorbid diagnosis. Most ofthe geriatric cases probably have an earlier onset. Although cases such as the current one may be regarded as being rare, their presence needs to be recognized, from a nosological perspective.
TC Ramesh Kumar, DPM, MD, GVL Raju, MBBS Sumant Khanna, MD, PhD, MRCPsych Bangalore, India
A Quick Rating Scale For Depression
During brief visits, a depression global rating scale may be useful to measure rapidly the severity ofdepression and treatment results. However, the Global Assessment of Functioning Scale (GAF), Clinical Global Impressions (CGI), and the Visual Analogue Scale (VAS) were not specifically designed to measure depression (1) . A possible alternative may exist in the item "Depressed Mood" found in the Positive and Negative Syndrome Scale (PANSS), General Psychopathology Scale (2) . This could be used as a global, specific depression rating scale, to obtain a score based on specific definitions of depression severity. The aim of the study described here was to test whether this item could indeed accurately measure depression severity when compared with the Montgomery Asberg Depression Rating Scale (MADRS) and the GAF (3, 4) .
Methods
The study was conducted in a private practice by a senior psychiatrist of the Department of Psychiatry of the National Health Service, located in Forli, Italy. In Italy, the private setting is more representative of treatment offered to patients with mood disorder. It is usually the first or the second line of treatment (after family doctors), although the most severely affected patients are usually seen in university centres or in the national psychiatric service. During the last 6 months, 142 outpatients who presented for treatment of major depressive episode (MDE) and suffered from major depressive/dysthymic, or bipolar II disorders were interviewed consecutively by the author. (Substance-related, severe personality, and bipolar I disorder patients have not been included, because they are rarely seen in private practice.) Diagnostic tools used were the Structured Clinical Interview for DSM-IV (5), MADRS, GAF, and the PANSS "Depressed Mood" item. This item score ranges from 1 to 7, and each point is linked to specific definitions of depression severity.
These definitions of depression severity should increase the score's accuracy and reliability. Severe depression was defined by a GAF score of 50 or less (6) and by a PANSS "Depressed Mood" score of 6 or 7 (as suggested by its guide). Because GAF scores were not normally distributed (Skewness and Kurtosis test), scales were correlated with the nonparametric Spearman test. Sensitivity and specificity of the PANSS "Depressed Mood" item for severe depression were calculated.
Results
Sample features were the following: bipolar II 41.5%; MDE with atypical features 32.3%; mean age 45.9 years (SD 14.0); women 66.9%; mean GAF 51.9 (SD 9.3); mean MADRS 30.1 (SD 9.0); mean PANSS "Depressed Mood" 5.4 (SD 0.7); 57.7% of patients had GAF 50 or less, 50.7% had MADRS 30 or more, and 54.3% had PANSS "Depressed Mood" 6 or 7.
GAF and PANSS "Depressed Mood" were significantly and strongly correlated (rho = -0.89, P = 0.0000). MADRS and PANSS "Depressed Mood" were significantly and strongly correlated (rho = 0.73, P = 0.0000). PANSS "Depressed Mood" score of 6 or 7 for severe depression had sensitivity 93.9%, specificity 100%, positive predictive value 100%, and negative predictive value 92.3%.
Discussion
The PANSS "Depressed Mood" score of 6 or 7 for severe depression had few false negatives and no false positives, meaning that it may identify severe depression accurately. Strong correlations with MADRS and GAF suggest that it may grade depression severity accurately. It might therefore be used as a global rating scale for rapidly assessing the severity of depression. However, nonblind assessment by the author requires the replication of these findings in blind studies.
vo145,No2 Mr B is a 29-year-old man who was diagnosed at age 20 years with chronic paranoid schizophrenia. Because he had not satisfactorily responded to various typical (haloperidol, pimozide, fluphenthixol, loxapine) and newer (risperidone, olanzapine) antipsychotic drugs, he was commenced on clozapine. Except for some fluctuations in mood, he responded satisfactorily to clozapine and remained on 800 mg daily (the maximum tolerated dose). His blood clozapine and norclozapine concentrations remained within the therapeutic levels. He did, however, develop some side effects. In particular, myoclonic jerks were observed in both hands, arms, and shoulders, along with excessive weight gain. (His weight prior to commencing clozapine was 92.5 kg, whereas 25 months after commencing clozapine it had increased to 138 kg-a 45.5 kg increment.) These side effects were severe enough that the patient attempted to discontinue clozapine.
Topiramate is a newer antiepileptic drug approved as adjunctive therapy for partial seizures in adults. Pharmacological studies suggest that its mode ofaction is multifactorial and involves blockade of voltage-dependent sodium channels, potentiation of GABAergic transmission, and inhibition of excitatory pathways through an action at AMP A receptor sites. Interestingly, weight loss appears to be a welldocumented side effect of this drug, and it may also have some mood-stabilizing properties (1) .
Mr B was commenced on topiramate with an initial dose of25 mg daily, and the dose was increased to 125 mg daily. There was no change in psychotic symptoms. There was some improvement ofhis mood, and myoclonic jerks improved completely. In addition, he started losing weight and lost 21 kg over 5 months. He reported no significant change in eating habits or food consumption but felt more energetic, more active, and more motivated to exercise. No side effects were reported. Although the mechanism of action for weight loss remains unclear, the addition of topiramate, in low doses, to clozapine may be recommended for such cases.
Visual and Auditory Hallucinations With the Association of Bupropion and Valproate
Bupropion is an interesting choice for patients with bipolar depression who present with anergia and attentional difficulties (1, 2) . The association ofbupropion and valproate has led to clinical observations ofcentral nervous system (CNS) side effects, particularly confusion, although, to our knowledge, no formal report has yet been published. Bupropion alone has been linked to 1 case of symptoms that mimic transient ischemic attacks with tinnitus and some cases of sensory disturbances (3) . Valproate, on the other hand, has been associated with cases of encephalopathy and confusion (4) (5) (6) .
We report the case ofa 45-year-old male patient with bipolarI disorder whose depression was quite improved by the association of lithium and bupropion. However, he experienced sexual dysfunction (impotence), and lithium was changed for valproate after a short overlap period. As soon as valproate was introduced, the patient, who had never been psychoticin the past, experienced auditory hallucinations. He reactedwith anxiety and feared that he was becoming crazy. His insight was preserved, and no paranoid ideas emerged. A week later, he presented with visual hallucinations.
When bupropion was reduced from 300 mg to 150 mg daily and then stopped, both visual and auditory hallucinations disappeared.
This side effect could be explained by a pharmacokineticinteraction between valproate and bupropion. Popli and others have already reported increased sodium valproate levels in the presence ofbupropion (7) , and rare cases ofacute psychosis have been previously described with increased valproate plasmatic levels (8) . Moreover, Ketter and others found increased metabolite hydroxybupropion concentrations associated with valproate, which also could have contributed to these side effects (9) .
From a pharmacodynamic perspective, it is well known that bupropion inhibits the reuptake ofdopamine into presynaptic neurons and does enhance extracellular dopamine levels in the nucleus accumbens after chronic administration, leading to the possibility of induced psychotic-like symptoms (8, 10, 11) . In fact, in clinical-controlled studies, 2 patients stopped their treatment after the appearance ofvisual or auditory hallucinations (12) . In addition, it has been reported that this antidepressant has precipitated hypomania or mania in patients with bipolar disorder (13) .
This interaction requires more careful attention since, in accordance with recent American and Canadian guideline recommendations, this combination is increasingly used to treat patients with bipolar disorder (14, 15) . Monitoring valproate and bupropion levels and their metabolites may ultimately prove useful in guiding dosing decisions to avoid troublesome side effects. In recent years, several studies have found similar prevalences of somatofonn disorders across countries. It is widely accepted that somatization is frequent all over the world and that cross-cultural differences are minimal. These studies, however, rely exclusively on the International Classification of Diseases (ICD-10) or DSM-IV diagnostic criteria of somatofonn disorders, and we think that other indices deserve to be used.
The 3 clinical forms of somatization described by Kirmayer-functional, hypochondriacal, and presenting somatization (FS, HS, PS)-represent different illness behaviours independent of the psychiatric diagnoses (1) . The patients that fit criteria for these forms present different sociodemographic, clinical, and diagnostic characteristics. Based on these characteristics, we propose the following 2 indices for transcultural comparisons in epidemiological research on somatization:
1) The somatizer:psychologizer ratio, defined as the number of somatizers in relation to the number ofpsychologizers in a population.
2) The overlapping percentage among the 3 forms of somatization, described as the percentage of somatizers who fit criteria for more than 1 form of somatization.
When comparing epidemiological data on somatization between Canada and Spain, the prevalence ofthe 3 forms of somatization is as follows: FS: 16.6% versus 16.2%; PS: 8% versus 9.4%; andHS 7.7% versus 6.7% (1,2). However, both the somatizer:psychologizer ratio and the overlapping of the 3 forms in Spain (3.2: 1 and 42% respectively) are double that in Canada (1.6: 1 and 21%). Thus, although both countries present similar prevalence data, the characteristics ofsomatization are different: the somatization indices we have proposed are higher in Spain than in Canada.
We have also summarized the main studies on somatization in primary-care settings, and we have calculated the somatizer:psychologizer ratio based on the data for each study. In less socioeconomically developed countries (according to Human Development measured by the United Nations' 1998 Report) such as Britain and Spain the ratio is over 3:1. In contrast, for more socioeconomically developed countries such as Canada and Holland, this ratio is under 2:1 (3-6). Thus, an inverse relationship seems to exist between socioeconomic development and the somatization:psychologization ratio.
In conclusion, the transcultural comparison of epidemiological data on somatization should include more indices than the mere prevalence of somatofonn disorders. We propose the use of2 new indices, and we suggest that both ofthem are inversely related to the level of socioeconomic development in the population studied. The main limitation ofthese indices is the uncertainty that differences among countries are due exclusively to transcultural causes and not to any other factors. For this reason, specifically designed studies are necessary to confirm their validity.
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Bupropion Treatment-Related Sexual Side Effects: A Case Report
The literature suggests that bupropion, a new nontricylic antidepressant, has reduced potential for sexual side effects due to its apparent lack of anticholinergic and antiadrenergic effect (l). Further, it has also been suggested that bupropion may have a positive effect on deficient sexual function, based on the documented association between bupropion treatment and increased adrenal androgen (dehydroepiandrosterone) adrenergic (alpha 1) activity, dopamine neurotransmission, and decreased prolactin concentration (2) . Hence, adjunctive use of bupropion (3, 4) and a switch to bupropion (5) have been recommended for patients who developed selective serotonin reuptake inhibitor (SSRI) treatment-emergent sexual side effects. In contrast to previous reports, we observed a case of diminished sexual arousal and anorgasmia that developed after bupropion was added to a regimen of paroxetine, lithium carbonate, and tryptophan.
Case Report
Ms M is a 38-year-old female with a history ofbipolar II disorder and alcohol abuse in remission who was hospitalized after a recurrence of depression. Physical examination and laboratory tests were normal. The upward titration oflithium carbonate from 300 mg to 900 mg daily (lithium level 1.07 mmollL) daily and paroxetine from 30 mg to 60 mg daily resulted in only minimal improvement. Further, addition of tryptophan 2 gm daily was ineffective in treating the depressed mood, anergia, and amotivation. Zopiclone 7.5 mg daily was given orally at bed time for insomnia. After 4 weeks, bupropion sustained-release (SR) formulation was added and gradually increased to 300 mg daily over a period of 2 weeks. Paroxetine was decreased from 50 mg to 40 mg daily when bupropion treatment was commenced. Approximately 7 days after reaching maximal doses ofbupropion, the patient noticed significant improvement in her energy level, motivation, and depressed mood. There was no suggestion of hypomania in her symptomatology while recovering from depression. However, during the same period, the patient complained of inner tremulousness, increased anxiety, palpitation, and sweating, which she had not experienced in the past. In addition, she also reported that, when she stayed with her boyfriend on a weekend pass, she experienced decreased sexual arousal, decreased lubrication, and delayed orgasm. These sexual and anxiety symptoms improved when bupropion SR was reduced from 300 mg to 200 mg daily. A compensatory increase in paroxetine from 40 mg to 50 mg daily had no adverse effect on her sexual functioning. She remained normothymic on this combination of medication at the same doses, and she was subsequently discharged.
Discussion
Sexual side effects emerged during upward titration of bupropion and normalized following reduction in bupropion, establishing a causal relationship between sexual side effects and bupropion treatment. It is highly unlikely that high doses of paroxetine alone contributed to the sexual side effects because these side effects emerged when paroxetine was reo duced from 50 mg to 40 mg daily and sexual functioning was normalized despite upward titration of paroxetine to 50 mg daily. Further, the patient did not report sexual disturbances while taking paroxetine in combination with lithium carbonate, tryptophan, and zopic1one before the addition of bupropion to the treatment regimen.
Interestingly, this patient experienced no adverse effects on sexual functioning with high doses ofparoxetine, although it belongs to the family ofSSRIs that are known to cause sexual side effects (6) . Yet, disturbances in sexual function emerged after the addition ofbupropion, an antidepressant with a low propensity for inducing sexual dysfunction. Although the exact reasons for the observed sexual side effects remain unclear, at least 2 possible explanations might account for the development of sexual dysfunction in our patient. First, the adrenergic and dopaminergic activity ofbupropion may have exerted stimulating and energizing effects on the patient. Hence, the nervousness and agitation associated with bupropion treatment may have interfered with sexual desire and orgasms (2) .The emergence of anxiety and agitation along with sexual dysfunction during the course ofupwardtitration ofbupropion treatment, and the resolution ofthese disturbances following the reduction ofbupropion, may suggest that sexual side effects and anxiety symptoms are closely associated.
The second possibility is that drug interactions betweenparoxetine and bupropion might have induced anxiety symptoms and related sexual disturbances. Paroxetine might have impaired cytochrome P4502D6 (CYP2D6) with a resultant increase in plasma level ofhydroxy bupropion metabolites (7) . Clinicians should be aware ofthe possibility that bupropion at higher doses, or at higher plasma level, may be associated with sexual dysfunction due to its anxiogenic side effect.The reduction in the dose ofbupropion may be a practical andeffective treatment option to resolve this side effect.
Increased Susceptibility to Seasonal Cardiovascular Death in the Elderly and Seasonal Mood Changes
Multiple lines ofevidence indicate a seasonal variation in cardiovascular morbidity and mortality (1) . I have recently suggested that seasonal mood changes may contribute to the increased incidence of acute myocardial infarction in winter (2, 3) . My suggestion was based on the facts that seasonality of mood and behaviour is common throughout the general population (4) and that, in patients with depressive disorders, cardiovascular morbidity and mortality are increased (5) .
It has recently also been found that seasonal variation in cardiovascular mortality is more pronounced in elderly persons than in younger individuals. Sheth and others have reviewed data from 300 000 deaths in the Canadian Mortality Database and propose that climatic factors may playa role in seasonal variation, causing risk factors (for example, cholesterol level and blood pressure) to be higher in winter than in summer (6) .
The observation by Sheth and others supports the hypothesis that seasonal mood changes may contribute to the increased incidence of heart attacks in winter (2,3) because depressive symptoms are not uncommon in the elderly (7, 8) . More than 25% ofelderly individuals have experienced at least 1 period of2 weeks or longer when they felt sad or blue, and more than 20% have experienced a period of 2 weeks or longer when they had recurrent thoughts of death and dying (7) . Depressive disorders in the elderly often are not diagnosed (8) . Yet, while age itselfis not a risk factor for the development of depressive disorders, being widowed, socially isolated, or having a medical illness--eonditions common to old age-are associated with increased vulnerability to depression (9) . In addition, depressive disorder may be associated with medications used for the treatment of physical illnesses.
Those elderly patients with cardiovascular disorders who suffer from seasonal mood changes should be identified and should receive treatment that may improve their quality of life and reduce their incidence ofcardiac death. Light therapy is a safe and effective treatment for winter depression (10) that may be used to treat elderly people with seasonal changes in mood. Evidence supporting the benefits oflight therapy for the geriatric population is provided in a recent study indicating that exposure to bright light may play an important rolein improving mood in elderly patients living in nursing homes (11).
Contemporary techno medicine does not pay much attention to the complex relation between mind and body. However, the influence ofpsychological factors on the physical condition ofelderly people is very considerable (8, 9, 12) and should not be underestimated.
Leo Sher, MD Bethesda, Maryland

A Case of Partial Lycanthropy
Lycanthropy can be clinically defined as the presence ofa delusion of human-to-wolf transformation. Perceptual abnormalities may accompany the delusion and may include sensations or visual perceptions ofhair growth or other bodily changes (1, 2) . Delusional and perceptual phenomena in lycanthropy can be to a certain extent compartmentalized, leading to cases ofpartial lycanthropy, wherein an individual may experience perceptual disturbances and delusions of hair growth but not have delusions ofhuman-to-wolfchange (3).
Case Report
Mr A is a 46-year-old male who experienced delusional episodes that lasted up to several hours. During these episodes, he had sensations ofhair growth on his face, trunk, and arms. Occasionally, he became convinced that the hair growth was real. He also complained that he experienced structural facial malformations and lesions that took place within minutes and remained for hours. He thought these changes would make him appear to be a wolf, and avoided seeing his face or body whenever possible. However, he did not believe that he was a wolf. He denied that his mind was changing into a different mind or that he was a different person from his objective self. Mr A avoided watching films (such as werewolf films) with plots involving bodily transformations because they made him apprehensive. He met DSM-IV diagnostic criteria for psychotic disorder not otherwise specified. Vol 45, No2 Delusions of hair transformation without delusions affecting self-identity are rare, although Verdoux and Bourgeois report a similar case in which a 45-year-old man believed that he had grown excessive hair and, upon viewing himself in a mirror, stated that he "had the head of a wolf' (3). In neither case, however, did the individual suffer from the delusional conviction that he was actually a wolf, even though each believed that he appeared to be a wolf. If they had also suffered from delusions ofhuman-to-wolf transformation, they would have qualified as suffering from a classic case oflycanthropy (1, 2) . Visual perceptual abnormalities that contributed to delusional beliefs about bodily changes were present in the index case and are common in cases involving delusions of transformation (1, 2, 4) . Cases of delusional beliefs of excessive hair growth accompanied by visual perceptual abnormalities, but with nondelusional concerns about wolf or werewolf transformations, are known as partial lycanthropy (3) 
Tardive Dyskinesia From Low-Dose Risperidone
There have been several reports of tardive dyskinesia (TD) occurring in patients receiving risperidone (1) (2) (3) (4) (5) . However, in those reports the TD occurred after relatively lengthy exposure to high dosages, or in conjunction with an additional antipsychotic. We report a case of persistent TD in a patient following a short trial of risperidone at a low dose.
Case Report
Mrs W is a 74-year-old female who has a history ofright renal nephrectomy for stage II renal cell carcinoma, hypertension, and alcohol abuse. Mrs W's psychiatric history is unremarkable. Following left knee replacement the patient was referred to a geriatrician for assessment of anxiety and depressive symptoms. The patient refused a trial of an antidepressant, but was willing to take loxapine 2.5 mg twice daily to treat her anxiety. After 1 week, oral extrapyramidal side effects (EPS) appeared, and the loxapine was discontinued. Risperidone was then started at a dose of0.5 mg twice daily. This medication was discontinued 3 weeks later because the patient experienced sedation and fatigue. Two weeks later, the patient's anxiety symptoms worsened, and the medication was restarted. At that time, no movement disorder side effect wasreported. However, 3 weeks after restarting the risperidone the patient was referred to our neuropsychiatric clinic for management of TD.
Following an initial assessment, the patient was prescribed benztropine to manage her side effects. She exhibited features of TD that included oral, truncal, and limb movements. She scored 15 on the Abnormal Involuntary Movement Scale (AIMS). After discontinuation of the risperidone, her TD worsened, and 1 month later she scored 19 on the AIMS. Nine months after our initial assessment her TD persists. Initially, tetrabenazine at a dose of 12.5 mg 3 times daily completely eliminated her TD. However, it caused severe parkinsonism. Trials of thiamine, vitamin E, benztropine, and quetiapine have improved her TD moderately; she now scores 7 on the AIMS. Her current medications are quetiapine 25 mg every morning, 50 mg at bed time, and tetrabenazine 12.5 mg twice daily.
Being elderly, having an affective disorder, and displaying extrapyramidal signs early in treatment are risk factors fordeveloping TD. However, the relative risk has only been established using conventional antipsychotics (6) . To date, there have been few studies that determine the relative risk ofID associated with risperidone (7) . In this report, we describe a patient who had the above-noted risk factors and developed TD after exposure of only 2 months to low-dose risperidone. Further research is required to establish the rates and riskfactors for TD associated with the use of risperidone in the elderly population.
